JP2017532048A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532048A5 JP2017532048A5 JP2017519981A JP2017519981A JP2017532048A5 JP 2017532048 A5 JP2017532048 A5 JP 2017532048A5 JP 2017519981 A JP2017519981 A JP 2017519981A JP 2017519981 A JP2017519981 A JP 2017519981A JP 2017532048 A5 JP2017532048 A5 JP 2017532048A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- seq
- binding fragment
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 238000006467 substitution reaction Methods 0.000 claims 13
- 150000001413 amino acids Chemical class 0.000 claims 12
- 102000003812 Interleukin-15 Human genes 0.000 claims 11
- 235000001014 amino acid Nutrition 0.000 claims 8
- 229940024606 amino acid Drugs 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000012472 biological sample Substances 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 4
- 235000004279 alanine Nutrition 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 235000013922 glutamic acid Nutrition 0.000 claims 4
- 239000004220 glutamic acid Substances 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 3
- 239000004473 Threonine Substances 0.000 claims 3
- 206010052779 Transplant rejections Diseases 0.000 claims 3
- 244000052616 bacterial pathogen Species 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000002503 metabolic effect Effects 0.000 claims 3
- 229930182817 methionine Natural products 0.000 claims 3
- 244000045947 parasite Species 0.000 claims 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 2
- 108010068370 Glutens Proteins 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 208000021329 Refractory celiac disease Diseases 0.000 claims 2
- 101000840183 Schizosaccharomyces pombe (strain 972 / ATCC 24843) 60S ribosomal protein L39 Proteins 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 235000021312 gluten Nutrition 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 210000004347 intestinal mucosa Anatomy 0.000 claims 2
- 229960000310 isoleucine Drugs 0.000 claims 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 101710187878 60S ribosomal protein L39 Proteins 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 206010010317 Congenital absence of bile ducts Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 208000008913 Hantavirus Infections Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 230000009830 antibody antigen interaction Effects 0.000 claims 1
- 201000005271 biliary atresia Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940126523 co-drug Drugs 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000010227 enterocolitis Diseases 0.000 claims 1
- 208000029629 hantavirus infectious disease Diseases 0.000 claims 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 244000052613 viral pathogen Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14175361.6 | 2014-07-02 | ||
| EP14175361.6A EP2963057A1 (en) | 2014-07-02 | 2014-07-02 | Antibodies to IL-15 |
| PCT/EP2015/064931 WO2016001275A1 (en) | 2014-07-02 | 2015-07-01 | Antibodies to il-15 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532048A JP2017532048A (ja) | 2017-11-02 |
| JP2017532048A5 true JP2017532048A5 (enExample) | 2018-06-28 |
| JP6563012B2 JP6563012B2 (ja) | 2019-08-21 |
Family
ID=51033041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017519981A Active JP6563012B2 (ja) | 2014-07-02 | 2015-07-01 | Ｉｌ−１５に対する抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10301384B2 (enExample) |
| EP (2) | EP2963057A1 (enExample) |
| JP (1) | JP6563012B2 (enExample) |
| CN (1) | CN106661106B (enExample) |
| AU (1) | AU2015282957B2 (enExample) |
| CA (1) | CA2952140A1 (enExample) |
| DK (1) | DK3164414T3 (enExample) |
| ES (1) | ES2800158T3 (enExample) |
| IL (1) | IL249187B (enExample) |
| PL (1) | PL3164414T3 (enExample) |
| PT (1) | PT3164414T (enExample) |
| WO (1) | WO2016001275A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201892707A1 (ru) * | 2016-06-15 | 2019-05-31 | Амген Инк. | Способы и композиции для лечения целиакии, непереносимости глютена без целиакии и рефрактерной целиакии |
| US20180002417A1 (en) | 2016-06-15 | 2018-01-04 | Celimmune Llc | Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease |
| FI3558369T3 (fi) * | 2016-12-21 | 2025-05-02 | Cephalon Llc | Spesifisesti ihmisen il-15:een sitoutuvia vasta-aineita ja niiden käyttötapoja |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| CA3064435A1 (en) | 2017-05-24 | 2018-11-29 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| AR114112A1 (es) | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | Anticuerpos de glipicano 3 y conjugados de los mismos |
| EP3827079A1 (en) | 2018-07-25 | 2021-06-02 | Askgene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| AU2020291012B2 (en) | 2019-06-12 | 2025-09-25 | AskGene Pharma, Inc. | Novel IL-15 prodrugs and methods of use thereof |
| KR102265430B1 (ko) * | 2019-08-20 | 2021-06-15 | 주식회사 케어젠 | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| UY39896A (es) | 2021-08-12 | 2023-02-28 | Amgen Inc | Formulaciones de anticuerpos |
| EP4565327A1 (en) | 2022-08-04 | 2025-06-11 | Novartis Pharma AG | Il-15 inhibitors useful for the treatment of atopic dermatitis |
| CN118894934A (zh) * | 2023-05-05 | 2024-11-05 | 北京智仁美博生物科技有限公司 | 抗人il-15的抗体及其用途 |
| CN117209605B (zh) * | 2023-11-09 | 2024-01-30 | 北京百普赛斯生物科技股份有限公司 | 特异性结合il-15的抗体及其应用 |
| KR102673861B1 (ko) * | 2024-01-12 | 2024-06-13 | (주)케어젠 | 근육 감소 억제 및 근육량 증가 활성을 갖는 신규 펩타이드 및 이의 용도 |
| CN118909143B (zh) * | 2024-10-12 | 2024-12-13 | 成都海默云因医学检验实验室有限公司 | 一种重组蛋白及其用细胞免疫荧光法在抗Hu抗体中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA014802B1 (ru) | 2001-08-23 | 2011-02-28 | Генмаб А/С | АНТИТЕЛА К ИНТЕРЛЕЙКИНУ 15 (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ, ИММУНОКОНЪЮГАТ НА ИХ ОСНОВЕ, ГИБРИДОМА, ТРАНСФЕКТОМА, ТРАНСГЕННОЕ ЖИВОТНОЕ, ЭКСПРЕССИОННЫЙ ВЕКТОР (ВАРИАНТЫ) И НУКЛЕИНОВАЯ КИСЛОТА ДЛЯ ИХ ПОЛУЧЕНИЯ, СПОСОБ ЛЕЧЕНИЯ (ВАРИАНТЫ) И СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ ИЛ-15, СПОСОБ ИНГИБИРОВАНИЯ ИНДУЦИРОВАННОЙ ИЛ-15 ПРОДУКЦИИ TNF-α И СПОСОБ ИНГИБИРОВАНИЯ ИНДУЦИРОВАННОЙ ИЛ-15 ПРОЛИФЕРАЦИИ КЛЕТОК |
| US7247304B2 (en) * | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
| RS20050724A (sr) * | 2003-02-26 | 2007-11-15 | Genmab A/S., | Humana antitela specifična za interleukin 15(il-15) |
| US20050123542A1 (en) * | 2003-11-06 | 2005-06-09 | Genmab A/S | Methods for treating disorders involving monocytes |
| KR20100086383A (ko) * | 2009-01-22 | 2010-07-30 | 강원대학교산학협력단 | 인터루킨-15 또는 종양 괴사 인자에 특이적으로 결합하는 항체 또는 항원 결합 단편 |
| CN102250243B (zh) * | 2011-07-01 | 2013-08-28 | 华绍炳 | 抗白细胞介素-15抗体 |
-
2014
- 2014-07-02 EP EP14175361.6A patent/EP2963057A1/en not_active Withdrawn
-
2015
- 2015-07-01 CN CN201580035080.7A patent/CN106661106B/zh active Active
- 2015-07-01 PT PT157319765T patent/PT3164414T/pt unknown
- 2015-07-01 PL PL15731976T patent/PL3164414T3/pl unknown
- 2015-07-01 US US15/320,763 patent/US10301384B2/en active Active
- 2015-07-01 JP JP2017519981A patent/JP6563012B2/ja active Active
- 2015-07-01 ES ES15731976T patent/ES2800158T3/es active Active
- 2015-07-01 CA CA2952140A patent/CA2952140A1/en active Pending
- 2015-07-01 EP EP15731976.5A patent/EP3164414B1/en active Active
- 2015-07-01 DK DK15731976.5T patent/DK3164414T3/da active
- 2015-07-01 AU AU2015282957A patent/AU2015282957B2/en active Active
- 2015-07-01 WO PCT/EP2015/064931 patent/WO2016001275A1/en not_active Ceased
-
2016
- 2016-11-24 IL IL249187A patent/IL249187B/en unknown
-
2019
- 2019-05-24 US US16/421,509 patent/US11130806B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532048A5 (enExample) | ||
| JP7631485B2 (ja) | キメラポックスウイルス組成物及びその使用 | |
| Li et al. | Autocrine CTHRC1 activates hepatic stellate cells and promotes liver fibrosis by activating TGF-β signaling | |
| RU2020123735A (ru) | Способ лечения рака | |
| JP2019506841A5 (enExample) | ||
| JP2019523753A5 (enExample) | ||
| JP2017537084A5 (enExample) | ||
| US20130195871A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| JP2010502207A5 (enExample) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| CN111107866A (zh) | 用于免疫疗法的pde5组合物和方法 | |
| BR112021003410A2 (pt) | anticorpos de domínio único anti-bcma, grupo de genes dos ditos anticorpos, polipeptídeo, vetor de expressão, célula hospedeira, receptor de antígeno quimérico, célula t modificada pelo mesmo, composição farmacêutica e usos dos ditos anticorpos | |
| RU2012149227A (ru) | Биологические материалы, относящиеся к her3 | |
| RU2012118636A (ru) | Молекула, специфически связывающаяся с rsv | |
| TW201726724A (zh) | 用於乳腺癌和其他癌症免疫治療的新型肽和肽組合物 | |
| JP2021501787A (ja) | 統合的ストレス経路の調節剤 | |
| JP2016521688A5 (enExample) | ||
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| JP2014510519A5 (enExample) | ||
| JP2013537418A5 (enExample) | ||
| JP2016524463A5 (enExample) | ||
| JP2017534259A5 (enExample) | ||
| AU2015320549A1 (en) | Peptidomimetic macrocycles and uses thereof | |
| JP2006506942A5 (enExample) | ||
| CN110981958A (zh) | 一种pd-l1抗体 |